IL-13 Blocker Beats Atopic Dermatitis

(MedPage Today) -- Lebrikizumab, an investigational interleukin (IL)-13 inhibitor seeking to join an increasingly crowded market for atopic dermatitis treatments, effectively reduced symptoms of the condition (a.k.a. eczema) when combined with...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news